BIBW 22, also known as Afatinib, is a potent irreversible inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases. It is primarily utilized in the treatment of non-small cell lung cancer (NSCLC) that harbors specific mutations in the EGFR gene. The compound exhibits a unique mechanism of action by covalently binding to the active site of the receptors, leading to prolonged inhibition of their signaling pathways, which are crucial for tumor growth and proliferation. BIBW 22 is characterized by its oral bioavailability and a relatively long half-life, allowing for once-daily dosing. Its chemical structure includes a quinazoline core, which is essential for its activity. The substance has undergone extensive clinical trials, demonstrating efficacy in patients with EGFR mutations, particularly those resistant to first-generation EGFR inhibitors. Common side effects associated with BIBW 22 include diarrhea, rash, and stomatitis, reflecting its impact on both tumor and normal epithelial tissues.

Bibw 22 is a bifunctional modulator of P-glycoprotein and nucleoside transport; may be useful as a modulator of combination chemotherapy involving compounds affected by multidrug resistance.

BIBW 22

137694-16-7: BIBW 22, also known as Afatinib, is a potent irreversible inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases. It is primarily utilized in the treatment of non-small cell lung cancer (NSCLC) that harbors specific mutations in the EGFR gene. The compound exhibits a unique mechanism of action by covalently binding to the active site of the receptors, leading to prolonged inhibition of their signaling pathways, which are crucial for tumor growth and proliferation. BIBW 22 is characterized by its oral bioavailability and a relatively long half-life, allowing for once-daily dosing. Its chemical structure includes a quinazoline core, which is essential for its activity. The substance has undergone extensive clinical trials, demonstrating efficacy in patients with EGFR mutations, particularly those resistant to first-generation EGFR inhibitors. Common side effects associated with BIBW 22 include diarrhea, rash, and stomatitis, reflecting its impact on both tumor and normal epithelial tissues.

Bibw 22 is a bifunctional modulator of P-glycoprotein and nucleoside transport.

CAS 137694-16-7

BIBW 22

Bibw 22

Ref: TM-T26803